Metabolic dysfunction–associated steatohepatitis (MASH) is a progressive form of liver disease that occurs when there's an accumulation of fat in the liver. MASH, which was formerly known as ...
In phase 2 trials involving patients with stage 2 or 3 fibrosis caused by metabolic dysfunction–associated steatohepatitis (MASH), efruxifermin, a bivalent fibroblast growth factor 21 (FGF21) analogue ...
Metabolic dysfunction-associated steatohepatitis (MASH) starts in your liver, but it can have body-wide effects. These effects increase your risk of conditions like heart disease, chronic kidney ...
Metabolic-associated steatohepatitis (MASH) happens when excess fat in the liver causes inflammation and scarring, or fibrosis. The condition is serious, and when left untreated it can lead to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback